Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Typical Teratoid Rhabdoid Tumor 1Pinealoma 1Paraganglioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma 1Choroid Plexus Neoplasms 1Astrocytoma 1

Interventions

gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 2belzutifan 2Fluorodeoxyglucose F18 2olaparib 1fludarabine phosphate 1Specimen Handling 1Phenoxybenzamine 1ONC206 1Magnetic Resonance Spectroscopy 1Interleukin-13 1Genetic Testing 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 13-fluorobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Paraganglioma × ONC206 × Clear all
NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Jazz Pharmaceuticals

Phase 2 Recruiting
90 enrolled
CNSEndocrine

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡